Form 4 for LXEO Lexeo Therapeutics, Inc.
Accepted 2025-10-17 00:00:00 ET · period of report 2025-10-15 · accession 0001994972-25-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-17 | 2025-10-15 | LXEO | Adler Eric | Chief Medical Off | A - Grant | $0.00 | +9,570 | 76.6K | +14% | $0 | |
| M | 2025-10-17 | 2025-10-17 | LXEO | Adler Eric | Chief Medical Off | S - Sale | $8.95 | -3,382 | 73.3K | -4% | -$30.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-15 | A | A | 9,570 | $0.00 | 76,643 | D | — | — | |
| 2 | Common | Common Stock | 2025-10-17 | S | D | 38 | $9.56 | 73,261 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F4) Includes 60,546 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. |
| 3 | Common | Common Stock | 2025-10-17 | S | D | 3,344 | $8.94 | 73,299 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |